Author:
Cannon Grant W.,DuVall Scott L.,Haroldsen Candace L.,Caplan Liron,Curtis Jeffrey R.,Michaud Kaleb,Mikuls Ted R.,Reimold Andreas,Collier David H.,Joseph George J.,Harrison David J.,Sauer Brian C.
Funder
Amgen Inc.
Health Services Research and Development
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),General Medicine
Reference40 articles.
1. Agarwal SK. Biologic agents in rheumatoid arthritis: an update for managed care professionals. J Manag Care Pharm. 2011;17:S14–8.
2. Moots RJ, Naisbett-Groet B. The efficacy of biologic agents in patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor inhibitors: a systematic review. Rheumatology (Oxford). 2012;51:2252–61.
3. Bonafede M, Joseph GJ, Princic N, Harrison DJ. Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis. J Med Econ. 2013;16:1120–8.
4. Schabert VF, Watson C, Gandra SR, Goodman S, Fox KM, Harrison DJ. Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United States. J Med Econ. 2012;15:264–75.
5. Schabert VF, Watson C, Joseph GJ, Iversen P, Burudpakdee C, Harrison DJ. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population. J Manag Care Pharm. 2013;19:621–30.